“Sam is an excellent scientist and a fantastic colleague. While technically strong, Sam also has a very good understanding of the bigger scientific picture. He is an excellent team player but highly capable of being innovative and effective when working on his own. He is respectful, engaging and highly motivated, a true asset to any team.”
Burlingame, California, United States
Contact Info
1K followers
500+ connections
Activity
-
What an awesome win for in vivo CAR: 3 out of 4 non-human primates showed deep B cell aplasia lasting 50 days or more. CAR was delivered to up to 65%…
What an awesome win for in vivo CAR: 3 out of 4 non-human primates showed deep B cell aplasia lasting 50 days or more. CAR was delivered to up to 65%…
Liked by Samuel Williams
-
It’s a bad day to be a pathogenic immune cell. Congratulations to the newest a16z Bio + Health portfolio company, Santa Ana Bio, Inc., on their…
It’s a bad day to be a pathogenic immune cell. Congratulations to the newest a16z Bio + Health portfolio company, Santa Ana Bio, Inc., on their…
Liked by Samuel Williams
-
Hello builders in bioinformatics! 👋 I’m excited to share Mantle’s first article in our Intro to Bioinformatics Engineering series. Please join us in…
Hello builders in bioinformatics! 👋 I’m excited to share Mantle’s first article in our Intro to Bioinformatics Engineering series. Please join us in…
Liked by Samuel Williams
Experience & Education
Publications
-
NF-kappaB RelA phosphorylation regulates RelA acetylation.
Mol Cell Biol.
-
Host factors regulating post-integration latency of HIV.
Trends Microbiol.
Patents
-
Identification and enrichment of cell subpopulations.
Filed US US9778264B2
Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations.
Other inventorsSee patent -
Anti-dll3 Antibodies And Drug Conjugates For Use In Melanoma
Filed US WO 2015/127407 A1
-
Methods And Compositions For The Synergistic Activation Of Latent HIV
Issued US US 8247613 B2
-
Anti-DLL3 Antibodies And Drug Conjugates For Use In Melanoma
US10308721
Recommendations received
2 people have recommended Samuel
Join now to viewMore activity by Samuel
-
I’m happy to share that I’m starting a new position as Head of Business Development at Factorial Biotechnologies! We develop single cell *DNA*…
I’m happy to share that I’m starting a new position as Head of Business Development at Factorial Biotechnologies! We develop single cell *DNA*…
Liked by Samuel Williams
-
Since TegMine was founded with the mission to develop high specificity, high affinity antibodies against cancer glycans and cancer glycoproteins…
Since TegMine was founded with the mission to develop high specificity, high affinity antibodies against cancer glycans and cancer glycoproteins…
Liked by Samuel Williams
-
At #ASGCT2024, the ArsenalBio team will be presenting the progress on the company’s research work. Nickolas Attanasio will present on our work to…
At #ASGCT2024, the ArsenalBio team will be presenting the progress on the company’s research work. Nickolas Attanasio will present on our work to…
Liked by Samuel Williams
-
Tarlatamab (CD3xDLL3) is now the FIRST FDA approved CD3-based bispecific for solid tumors. Great news for patients with small cell lung cancer. Let’s…
Tarlatamab (CD3xDLL3) is now the FIRST FDA approved CD3-based bispecific for solid tumors. Great news for patients with small cell lung cancer. Let’s…
Liked by Samuel Williams
-
It is great to present at the SID annual meeting some of the latest research from Rubedo Life Sciences
It is great to present at the SID annual meeting some of the latest research from Rubedo Life Sciences
Liked by Samuel Williams
-
Thrilled to welcome Lindsay Mazotti, MD, FACP as Sutter’ first Chief Medical Officer of Medical Education and Science. As part of #TeamSutter…
Thrilled to welcome Lindsay Mazotti, MD, FACP as Sutter’ first Chief Medical Officer of Medical Education and Science. As part of #TeamSutter…
Liked by Samuel Williams
-
💸 It was a busy week of fundraising for biotech and pharma. See below for the most notable deals, including 5x $100M+ equity financings… 👇 🔬…
💸 It was a busy week of fundraising for biotech and pharma. See below for the most notable deals, including 5x $100M+ equity financings… 👇 🔬…
Liked by Samuel Williams
-
Today is my last day of an incredible journey. I want to express my gratitude to the Celgene Pharma/Bristol Myers Squibb family for a great 9 year…
Today is my last day of an incredible journey. I want to express my gratitude to the Celgene Pharma/Bristol Myers Squibb family for a great 9 year…
Liked by Samuel Williams
-
This Wednesday, May/15 at 3:30 tune in to some of the work we are doing at Synthekine to leverage the power of cytokines in immunotherapy. The talk…
This Wednesday, May/15 at 3:30 tune in to some of the work we are doing at Synthekine to leverage the power of cytokines in immunotherapy. The talk…
Liked by Samuel Williams
-
Great news to share again! So proud of the Bluejay team. We are on our way to deliver high impact medicine to patients with serious viral and liver…
Great news to share again! So proud of the Bluejay team. We are on our way to deliver high impact medicine to patients with serious viral and liver…
Liked by Samuel Williams
-
At today’s "Unlocking Complex Cell-based Gene Therapies" joint public meeting hosted by PICI and Friends of Cancer Research in Washington, DC, Carl…
At today’s "Unlocking Complex Cell-based Gene Therapies" joint public meeting hosted by PICI and Friends of Cancer Research in Washington, DC, Carl…
Liked by Samuel Williams
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Samuel Williams in United States
-
Samuel Williams
Product Strategy & Transformation
-
Samuel Williams
Area Recruitment Manager for Kappa Sigma Fraternity
-
Samuel Williams
-
Samuel Williams
2083 others named Samuel Williams in United States are on LinkedIn
See others named Samuel Williams